Pay in 4 interest-free payments of $6.70 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Halda Therapeutics has developed HLD-0915, a first-to-clinic RIPTAC therapeutic, which targets mCRPC (metastatic castration-resistant prostate cancer)
Even if you believe a medication is insignificant, it is always better to mention it
A limitation of the current review is that it focused on indirect comparisons of 24-h continuous monitoring studies that differed in terms of study population (e.g., obese or not-obese, ambulatory or not-ambulatory), study treatment (e.g., continuous intravenous infusion, or oral administration) and timing of assessment after variable duration of study treatment
adults (~32 million people) have taken GLP-1 medications ( [1] ), and roughly 4% of all Americans (~13 million) were on a GLP-1 drug in 2024 ( [2] )
Our mission is to empower you with tailored care that fits your lifestyle, backed by licensed providers who prioritize your well-being
US$ 26.10
US$ 22.87
US$ 29.43
